NUWE · Nuwellis, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, including continued operating losses, negative cash flows from operations, an accumulated deficit of $325.7 million, and the need for additional capital to fund ongoing operations and growth initiatives (including the integration of Rendiatech Ltd., and Israeli company (“Rendiatech”) following the Company’s acquisition), raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the date these financial statements are issued. While management’s plans, including recent financing activities, cost discipline initiatives, and contingency measures, are intended to address these conditions, such plans do not alleviate the substantial doubt.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 26, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jun 26, 2026.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Critical care revenue increase | 28% | the first half of 2026 | — |
| Gross margin | 76% | the second quarter | — |
|
|
|||
| Gross proceeds raised | $6.7M | July 2026 (subsequent to June 30, 2026) | — |
| Heart failure revenue increase | 27% | the first half of 2026 | — |
| Pediatrics revenue increase | 29% | the first half of 2026 | — |
| U.S. circuit average selling price increase | 5% | the second quarter | — |
| U.S. console average selling price increase | 3% | the second quarter | — |
| U.S. revenue increase | 24% | the first six months of 2026 | — |
| Circuit average selling price increase | 11% | Q4 2025 | — |
| Critical Care revenue decline | 19% | FY2025 | — |
| Heart Failure revenue growth | 8% | FY2025 | — |
| International sales increase | 59% | Q4 2025 | — |
| Pediatrics revenue growth | 14% | FY2025 | — |
| U.S. console sales | 208% | Q4 2025 | — |
| U.S. console units | 8 | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NUWE
this stock
Nuwellis, Inc.
|
$4.78M | — | -5.4% | — | 26.2% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.6%
- Net QoQ
- +12.7K sh
- Top holder
- ARMISTICE CAPITAL, LLC
Performance
Raw-price comparisons begin at the captured split on Jun 26, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NUWE | -12.1% | -54.0% | — | -24.7% | — |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -12.5% | -58.5% | — | -28.6% | — |